TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
|
|
- Aubrey Burke
- 5 years ago
- Views:
Transcription
1 TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, C. Lai, K. Duong-Polk, A. Tjitro, D.C. Ince, J. Stewart, L. Dellamary, B. Hofilena, G. Mittapalli, S. KC and Y. Yazici AAT AD/PD Focus Meeting Turin March 15 th, 2018
2 X Samumed, LLC X X 2
3 Disclaimer This presentation is not intended to provide a comprehensive overview of all studies using SM SM07883 is an investigational compound; SM07883 has not been approved by the US Food and Drug Administration (FDA) or any other pharmaceutical regulatory authority, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. While the complete mechanism of action (MOA) for SM07883 is unknown, further investigation is being conducted. All of the MOA information is based on non-clinical data and the relationship to clinical benefit is unknown. This presentation is intended as a scientific exchange of medical information, is provided for educational purposes only, and is not intended for any promotional purpose or to offer medical advice; the information contained in this presentation is confidential and proprietary and is not available for further distribution in any form whatsoever.
4 AD pathophysiology and potential therapeutic targets Tau phosphorylation SM07883 Amyloid Precursor Protein SM07883 Tau aggregation Aβ fragments Neurofibrillary Tangles SM07883 Inflammation Amyloid Plaques SM07883 Synaptic impairment & Neurodegeneration Alzheimer s Disease Memory Loss Agitation Dementia Choi SH, et al. Nature Manassero G, et al. Aging Cell Selkoe, DJ Nat Cell Biol Heneka, MT et al., Lancet Neurol Crews L and Masliah E. Hum Mol Genet Manning G, et al. Science. 2002
5 Tau hyperphosphorylation and pathology Tau protein Hyperphosphorylated Tau Tau oligomer Oligomers spread to unaffected neurons Postsynaptic neuron Tau hyperphosphorylation Presynaptic neuron X Tau oligomerization Tau aggregation NFT SM07883 NFT staining in hippocampus of a 63 year old AD patient Tau hyperphosphorylation causes oligomerization and aggregation leading to neurofibrillary tangles (NFTs) 1 Tau oligomers are believed to spread across the synapse to unaffected neurons 2 SM07883 blocked hyperphosphorylation in rodents and inhibited downstream effects leading to NFTs and neuronal degeneration 1. Selkoe, DJ Nat Cell Biol Walsh, DM & Selkoe, DJ. Nat. Rev. Neurosci Tau Pathway figures adapted from Šimić, G. et al. Biomolecules NFT Illustration adapted from Alzheimer s Disease Research, a program of the BrightFocus Foundation.
6 Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) contributes to AD pathology DYRK1A: DYRK1A Activation Elevated expression in AD brains and in Down Syndrome patients (on chromosome 21) 1,2 Tau Phosphorylation by DYRK1A RCAN-1 Phosphorylation by DYRK1A STAT3 phosphorylation Presenilin Phosphorylation by DYRK1A APP Phosphorylation by DYRK1A Regulates phosphorylation of Tau, 1,2 APP, 3 Presenilin 4 Regulates inflammation (suppresses Th17 5, triggers T-regulatory cell differentiation 5, regulates STAT3 pathway 6 ) Tau Phosphorylation by GSK-3b and other kinases Caln Phosphatase Activity Expression of Phosphorylated Tau Pro-Inflammatory cytokines g-secretase Protease Activity b/g-secretase- Mediated Cleavage of APP Ab Primes and regulates GSK3b 7 Tau Aggregation Neuroinflammation Image adapted from Hume, C accessed 12/18/17 1. Ferrer et al., Neurobiol. Dis Ryoo, S. R. et al. J. Neurochem Branca, C. et al. Aging Cell Ryu, Y. S. et al. J. Neurochem Khor, B. et al. Elife Kurabayashi, N., et al., EMBO Rep Song, WJ. et al. J. Biol. Chem Neurofibrillary Degeneration Neuronal Death and Reduced Cognitive Functioning b-amyloidosis
7 SM07883 Drug Discovery
8 SM07883, a potent DYRK1A kinase inhibitor with a unique selectivity profile % In h ib itio n SM07883 DYRK1A kinase inhibition Kinases within 15 fold of DYRK1A IC IC 50 = 1.6 nm S M L o g C o n c. (n M ) In kinase inhibition screen assays of 414 kinases, SM07883 showed relatively specific and potent inhibition of DYRK1A 6 kinases within the 15-fold range of DYRK1A IC 50 Kinases IC 50
9 SM07883 inhibited Tau phosphorylation in vitro 3 p S ( A. U. ) p T (A.U.) DYRK1A induced Tau hyperphosphorylation in Tau/DYRK1A HEK293T cells Tau phosphorylation in a human neuroblastoma cell line (SH-SY5Y) pthr212 EC 50 = 13 nm 2 1 pser396 EC 50 = 184 nm S M L o g C o n c. (n M ) S M L o g C o n c. ( n M ) SM07883 potently inhibited DYKR1A mediated Tau hyperphosphorylation in two human cell lines
10 SM07883 Log Concentration (ng/ml) SM07883 Log Concentration (ng/ml) SM07883 is bioavailable, brain penetrant and has sustained therapeutic exposure in animals Mouse PK PO/IV administration Oral 5 mg/kg Brain Oral 5 mg/kg Plasma IV 2 mg/kg Plasma Mouse PK at 10mg/kg, PO administration Time (hr) Good bioavailability across species 35% 100% High permeability and limited efflux (Caco-2 Efflux ratio: 0.283) Brain / Plasma ratio: >3 in mice (F ub /F up =0.64); ~ 30% plasma free fraction across species; ~ 6% brain free fraction (rodent) High correlation of PK between brain, CSF and plasma; half life was consistent between plasma and brain Allometric projection >11hrs half life in human and potentially amenable to once a day dosing in human Plasma levels may be a surrogate for CNS exposure Targeted therapeutic concentration in plasma (60 ng/ml) t 1/2 ~4.25 hrs Brain Plasma CSF C max (ng/ml) Time (hr)
11 SM07883 Additional drug properties MW <400, solubility >50 mg/ml No brain or tissue accumulation over 3 months daily testing in mice Low intrinsic clearance; metabolic stability >960 min in human hepatocytes Low CYP inhibition (IC 50 >20 mm with CYP2C19 = 6.8 mm) Limited transporter inhibition (OCT2, MATE 1/2) with low potential for drugdrug interactions Limited off-target binding in panel with channels and receptors IC 50 >15 mm herg channel inhibition IC 50 of 0.6 µm
12 Animal toxicology and safety findings No cardiac abnormalities (e.g. QT prolongation, arrhythmia) were detected up to 50 mg/kg in monkey In vitro and in vivo studies demonstrated that SM07883 had low potential for genotoxicity in human No Observed Adverse Effect Level was 30x higher in AUC than the minimum efficacious dose (1.25 mg/kg/day) in mice 8x total exposure in monkeys (GI intolerance was the dose limiting factor, reversible) Suggested a broad therapeutic window for human dosing
13 Preclinical Tau efficacy studies
14 SM07883 reduced Tau hyperphosphorylation in the mouse brain P h o s p h o T a u (A T 8 / b -a c tin ) Single oral dose of SM07883 in wild type mice, followed (3 hr) by anesthesia-induced transient Tau hyperphosphorylation 1 with brain collection at 4h and western blot for ptau In d u c e d T a u h y p e rp h o s p h o ry la tio n *** SM07883 produced a dose dependent inhibition of ptau 0.5 *** *** *** *** Significant reduction of ptau after a single dose as low as 1.25 mg/kg compared to vehicle SM07883 follows free drug principle 0.0 N a ive V e h ic le m g /k g 2.5 m g /k g 5 m g /k g 1 0 m g /k g 2 5 m g /k g SM07883 Concentration Plasma (ng/ml) Brain (ng/ml) *** p<0.001 compared with vehicle 1. Bretteville et al., Scientific reports, 2012
15 Tau transgenic mouse model for preclinical efficacy JNPL3 mice carry a mutated form of human Tau from autosomal dominant Tau FTD patients In this model, Tau spreads from the brain stem and spinal cord Decreased motor coordination, no cognitive deficit Pathological Tau staining in the brain stem and spinal cord of JNPL3 mice (AT8 antibody, brown) The P301L mutation in JNPL3 mice results in Tau hyperphosphorylation at sites similar to AD brains (Thr181, Ser202/Thr205 [AT8 epitope], Thr212, Thr231, Ser396) JNPL3 mice (10 months old) treated with QD SM07883 for 14 weeks and evaluated for: Tau hyperphosphorylation Formation of Tau oligomers, aggregation, and NFTs Neuroinflammation Health and motor deficits Lewis, J. et al. Science 2001
16 L o g A T 8 In te n s ity (5 5 K D a b a n d ) / ß -a c tin L o g A T 8 b a n d in te n s ity (A.U.) SM07883 reduced Tau hyperphosphorylation in JNPL3 mice 1 0 Brainstem AT8 levels (Western Blot) 3 mg/kg 10 mg/kg * * W ild ty p e (n = 9 ) V e h ic le (n = 1 9 ) S M m g /k g q d (n = 1 9 ) 1 0 W ild ty p e (n = 1 0 ) V e h ic le (n = 1 5 ) S M m g /k g q d (n = 1 4 ) SM07883 (3 mg/kg or 10 mg/kg SM07883 QD) reduced Tau hyperphosphorylation in the brainstem at the AD pathogenic AT8 epitope (Ser202/Thr205) compared to vehicle * p<0.05 compared to vehicle
17 L o g A T 8 s ta in in g in te n s ity (A.U.) L o g A T 8 S ta in in g In te n s ity (A.U.) SM07883 prevented formation of insoluble Tau in JNPL3 mice AT8 in the sarkosyl-insoluble fraction 3 mg/kg (Western Blot) 10 mg/kg * ** W ild ty p e (n = 9 ) V e h ic le (n = 2 0 ) S M m g /k g q d (n = 1 9 ) 1 W ild ty p e (n = 1 0 ) V e h ic le (n = 1 5 ) S M m g /k g q d (n = 1 3 ) SM07883 (3 mg/kg or 10 mg/kg SM07883 QD) inhibited insoluble Tau formation in the brainstem at the AD pathogenic AT8 epitope (Ser202/Thr205) compared to vehicle (sarkosyl insoluble fraction) Only positive values plotted (eight 0 or negative values not shown 3 WT, 2 Veh, 3 SM07883) * p<0.05, ** p<0.01 compared to vehicle
18 T a u a g g re g a tio n (S ig n a l n m /S ig n a l n m x ) T a u a g g re g a tio n (S ig n a l n m /S ig n a l n m x ) SM07883 prevented Tau aggregation in JNPL3 mice Tau aggregates in the spinal cord 3 mg/kg (HTRF assay) 10 mg/kg * ** W ild ty p e (n = 9 ) V e h ic le (n = 1 9 ) S M m g /k g (n = 1 9 ) 0 W ild ty p e (n = 1 0 ) V e h ic le (n = 1 5 ) S M m g /k g (n = 1 3 ) SM07883 (3 mg/kg or 10 mg/kg SM07883 QD) inhibited Tau aggregation in the spinal cord compared to vehicle in a FRET (HTRF) based assay HTRF: Homogeneous Time Resolved Fluorescence * p<0.05, ** p<0.01 compared to vehicle
19 L o g P e rc e n t A T 8 s ta in in g / R O I SM07883 Vehicle SM07883 reduced the formation of NFTs in JNPL3 mice Brainstem NFTs (AT8 immunostaining) 3 mg/kg * W ild ty p e V e h ic le S M (n = 1 ) (n = 1 8 ) 3 m g /k g q d (n = 1 9 ) 10x magnification Computer magnified to show detail SM07883 (3 mg/kg QD shown) significantly reduced the formation of brainstem NFTs compared to vehicle * p<0.05 compared to vehicle
20 Wild Type Wild Type SM07883 SM07883 Vehicle Vehicle SM07883 reduced Tau-induced glial activation (neuroinflammation) in JNPL3 mice GFAP Staining Iba1 Staining Bulky reactive microglial cells 10x magnification Computer magnified to show detail 200 mm 200 mm SM07883 significantly reduced GFAP (astrocytes) and Iba1 (activated microglia) expression compared to vehicle in the brainstems of JNPL3 mice (representative images shown)
21 Im p ro v m e n t p o in ts (p ts o v e r 1 7 w e e k s ) SM07883 reduced functional deficits in Tau JNPL3 mice Motor Coordination (Wire Hang Test Performance) Task Improvement Score WT + vehicle 4 3 W ild ty p e (n = 1 0 ) J N P L 3 + V e h ic le (n = 1 9 ) J N P L 3 + S M m g /k g (n = 1 9 ) JNPL3 + vehicle 2 1 * JNPL3 + SM Combined score based on time in which the mice fall from the wire or reach the platform and grip score (motor coordination) SM07883 improved motor coordination in JNPL3 mice compared to Vehicle * P = compared to vehicle
22 W e ig h t (g ra m s ) W e ig h t d iffe re n c e (g ra m s ) SM07883 improved weight & reduced morbidity / mortality of JNPL3 mice 4 4 Animal Weight J N P L 3 + S M J N P L 3 + V e h ic le (3 m g /k g Q D ) 2 Weight change week 0 to 14 *** ω ω -1 W T + V e h ic le J N P L 3 + V e h ic le J N P L 3 + S M m g /k g Q D W e e k s ω = animal died -3 WT n=9, Vehicle n=20, SM07883 n=19; *** p<0.001 vs. JNPL3 + Vehicle JNPL3 mice have low body weight with incidence of morbidities and mortality SM07883 treatment significantly improved body weight and empirically improved morbidity / mortality compared to vehicle Morbidity / Mortality Vehicle SM07883 Death 2/20 0/19 Pronounced hunched back 1/18 0/19 Severe tremors 3/18 0/19 Moderate tremors 6/18 0/19 Mild tremors 0/18 2/19
23 Summary SM07883 is a potent DYRK1A inhibitor with a unique selectivity profile that reduces Tau hyperphosphorylation in mice In Tau transgenic mice daily SM07883 vs. vehicle control reduced: Tau hyperphosphorylation Formation of Tau oligomers and aggregation Formation of NFTs Glial activation SM07883 demonstrated sustained brain and CSF exposures and was stable in all species 28 day repeated dose studies in animals demonstrated acceptable tolerability and therapeutic margin SM07883 may provide therapeutic, disease modifying effects in AD IND-enabling studies are completed and a Phase 1 trial in healthy volunteers is planned
24 Thank you
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRKA INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, Carolyn Lai, Karen Duong-Polk, Amanda Tjitro,
More informationTargeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1
Targeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1 ADC Directors Meeting, April 18 th 2015 Frank M. Longo, Stanford
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationStem Cells and the Study of Neurodegeneration. Tracy Young-Pearse, PhD September 12, 2014!
Stem Cells and the Study of Neurodegeneration Tracy Young-Pearse, PhD September 12, 2014! Techniques for studying mechanisms of neurological disease Animal models Human subjects Postmortem analyses, imaging
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationSmall Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment
Small Molecule Inhibitor of the Wnt Pathway (SM755) as a Potential Topical Scleroderma Treatment Vishal Deshmukh, PhD, Allison Hood, Yusuf Yazici, MD Disclosures Vishal Deshmukh, Ph.D. o Financial disclosure:
More information9.01 Introduction to Neuroscience Fall 2007
MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 9.01 Recitation (R02)
More informationTTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers
TTI-2341: A Novel Brain-Penetrant, Orally Available, Covalent EGFR Inhibitor for the Treatment of Brain Cancers November 2017 2 EGFR is a Drug Target in Brain Cancer Epidermal growth factor receptor (EGFR)
More informationMicroglia, Inflammation, and FTD
FTD Minicourse April, 2009 Microglia, Inflammation, and FTD Li Gan, Ph.D Gladstone Institute of Neurological Disease University of California, San Francisco Outline Why study inflammation in neurodegeneration?
More informationThe Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461
The Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461 1 TABLE OF CONTENTS Profile Summary Mechanism of Action Clinical Study Results Pharmacologic Profile Safety and Toxicity
More informationAnti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis
Anti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis V. Deshmukh 1, T. Seo 1, C. Swearingen 1, Y. Yazici 1 1 Samumed,
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationSupplementary Figure 1
Supplementary Figure 1 AAV-GFP injection in the MEC of the mouse brain C57Bl/6 mice at 4 months of age were injected with AAV-GFP into the MEC and sacrificed at 7 days post injection (dpi). (a) Brains
More informationSafety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema
Safety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema IRA KALFUS, MD Attune Pharmaceuticals, LLC New York City, NY Andrew McDonald, PhD; Shawn Qian, PhD Attune Pharmaceuticals,
More informationCSF: Lessons From Other Diseases
CSF: Lessons From Other Diseases Consultant: AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva Research: Actelion, Novartis, Opexa Alzheimer s Progressive
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationNNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update
NNZ-2566 in Rett Syndrome and Autism Spectrum Disorders Role and Update 1 Overview The natural growth factor IGF-1 is broken down in the body to IGF-1[1-3] NNZ-2566 is an analogue of IGF-1[1-3] developed
More informationTau Mechanism in Dementia
ADC Directors Meeting Saturday, April 12, 2008 Sheraton V Tau Mechanism in Dementia Lennart Mucke, M.D. Director, Gladstone Institute of Neurological Disease Joseph B. Martin Distinguished Professor Department
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationEfficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B R Rush 1, J Greytok 2, T Matkovits 2, R Driz 2, JZ Sullivan-Bólyai 2, and D Standring 3 1 Allon
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationALM301: Allosteric Isoform selective Akt inhibitor
ALM301: Allosteric Isoform selective Akt inhibitor Background Akt1/2 selective inhibitors ALM301 Back-up compounds Akt2 selective inhibitors Approaches to Akt Inhibition Both ATP competitive and allosteric
More informationDelirium, Apo-E status, and AD CSF biomarkers
Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationThe Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05
The Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05 1 TABLE OF CONTENTS Highlights Clinical Trials Narcolepsy Profile Ancillary Pharmacology Mechanism of Action Preclinical Pharmacology
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationSelective filtering defect at the axon initial segment in Alzheimer s disease mouse models. Yu Wu
Selective filtering defect at the axon initial segment in Alzheimer s disease mouse models Yu Wu Alzheimer s Disease (AD) Mouse models: APP/PS1, PS1δE9, APPswe, hps1 Wirths, O. et al, Acta neuropathologica
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationResearch Development: Bedside to Bench and Back
Research Development: Bedside to Bench and Back Matt Bellizzi, MD PhD Department of Neurology University of Rochester School of Medicine and Dentistry Rochester, NY "I can walk down the hall just fine,
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationJ. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008
Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer s Disease J. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008 EPIX: GPCR Focused Drug Discovery
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationSoluble phospho-tau from Alzheimer's disease hippocampus drives. Elisabeth Sanchez-Mejias1,4*, Victoria Navarro2,3,4*, Sebastian Jimenez2,3,4,
Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration Elisabeth Sanchez-Mejias,, Victoria Navarro,,, Sebastian Jimenez,,, Maria Sanchez-Mico,,, Raquel Sanchez-Varo,, Cristina
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10353 Supplementary Figure 1. Mutations of UBQLN2 in patients with ALS and ALS/dementia. (a) A mutation, c.1489c>t (p.p497s), was identified in F#9975. The pedigree is shown on the left
More informationNigel Hooper. University of Manchester UK
Prion protein as a therapeutic target in Alzheimer s disease Nigel Hooper University of Manchester UK Prion protein and Alzheimer s a connection? - causative agent of transmissible spongiform encephalopathies
More informationMary ET Boyle, Ph. D. Department of Cognitive Science UCSD
? Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Christian S Lobsiger & Don W Cleveland (2007) Nature Neuroscience 10, 1355-1360 Astrocytes: interlinked gatekeepers of glutamate astrocytes
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationSupplementary Information
Supplementary Information Title Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis Authors Shin H. Kang, Ying Li, Masahiro Fukaya, Ileana Lorenzini,
More informationAnalysis of Chlamydia Pneumoniae and AD-like Pathology in the Brains of BALB/c Mice Following Direct Intracranial Infection with Chlamydia Pneumoniae
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Biomedical Studies Student Scholarship Student Dissertations, Theses and Papers 8-2011 Analysis of Chlamydia Pneumoniae and AD-like
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationWnt Signaling Pathway and AD
Center for Cell Regulation and Pathology Joaquín V. Luco (CRCP), Millennium Institute (MIFAB) Center for Aging and Regeneration (CARE). Wnt Signaling Pathway and AD Nibaldo C. Inestrosa European Union
More informationmarker. DAPI labels nuclei. Flies were 20 days old. Scale bar is 5 µm. Ctrl is
Supplementary Figure 1. (a) Nos is detected in glial cells in both control and GFAP R79H transgenic flies (arrows), but not in deletion mutant Nos Δ15 animals. Repo is a glial cell marker. DAPI labels
More informationHOMOTAURINE INVESTIGATIONAL SUMMARY
HOMOTAURINE INVESTIGATIONAL SUMMARY Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More informationPotential Best-In-Class Potent, Selective & Orally Active S1P 1 Agonists for Multiple Sclerosis
Potential Best-In-Class Potent, Selective & Orally Active S1P 1 Agonists for Multiple Sclerosis Art Taveras, PhD March 25, 2009 Therapeutic Hypothesis of S1P Agonism Multiple Sclerosis (MS): A chronic
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationMetformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
Barini et al. Molecular Neurodegeneration (2016) 11:16 DOI 10.1186/s13024-016-0082-7 RESEARCH ARTICLE Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationPotential role of extracellular tau in development and spread of tauopathy: Effects of anti-tau antibodies
Potential role of extracellular tau in development and spread of tauopathy: Effects of anti-tau antibodies David M. Holtzman, MD Professor and Chair, Dept. of Neurology Washington University School of
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationCB 1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of A PP/PS1 Mice
Journal of Alzheimer s Disease 30 (2012) 439 459 DOI 10.3233/JAD-2012-111862 IOS Press 439 CB 1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of A PP/PS1 Mice Ester Aso a,, Ernest
More informationFor personal use only. Annual General Meeting 13 November 2015
Annual General Meeting 13 November 2015 This presentation may contain some statements that may be considered Forward-Looking Statements, within the meaning of the US Securities Laws. Thus, any forward-looking
More informationInflammation in dementia
Inflammation in dementia V. Hugh Perry University of Southampton DPUK April 2018 Inflammation in Alzheimer s disease: consequence or contributor? Amyloid plaque Neurofibrillary tangle Nissl & Alzheimer
More informationTREATING NEUROINFLAMMATION, TREATING DISEASE
TREATING NEUROINFLAMMATION, TREATING DISEASE NeuroTherapia Developing novel biopharmaceuticals for the treatment of neuroinflammatory disorders NOVEL STRATEGY FOR REDUCING NEUROINFLAMMATION SIGNIFICANT
More informationCigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences
Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences Walter Royal, III, MD Professor of Neurology University of Maryland School of Medicine
More informationSection 5.3: Preclinical safety data
Section 5.3: Preclinical safety data SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationSynaptic changes in dementia: links to cognition and behaviour
Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias
More informationIn vivo effect of anti-inflammatory compounds on HIV-1 gp120 -mediated brain inflammation
In vivo effect of anti-inflammatory compounds on HIV-1 gp120 -mediated brain inflammation Tamima Ashraf, PhD candidate Supervisor: Dr. Reina Bendayan University of Toronto, Leslie Dan Faculty of Pharmacy,
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationBL-1020: First-in-Class GABA-Enhanced Antipsychotic For Schizophrenia
BL-1020: First-in-Class GABA-Enhanced Antipsychotic For Schizophrenia December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like
More informationThe Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina
The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain
More informationSupplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationNg et al. Molecular Neurodegeneration (2016) 11:71 DOI /s x
Ng et al. Molecular Neurodegeneration (216) 11:71 DOI 1.1186/s1324-16-136-x RESEARCH ARTICLE Open Access Chronic adiponectin deficiency leads to Alzheimer s disease-like cognitive impairments and pathologies
More informationAliso Hall, Room 234, One University Drive, Camarillo, CA The Effects of Melatonin on Tau Hyperphosphorylation in Hypothermic SH-SY5Y Cells
1 Research Lab: California State University: Channel Islands, Aliso Hall, Room 234, One University Drive, Camarillo, CA 93012 Sami Johnson The Effects of Melatonin on Tau Hyperphosphorylation in Hypothermic
More informationSCIRF Award #2016 I-03 PI: Azizul Haque, PhD Grant Title: Neuron-specific Enolase and SCI
SCIRF Award #2016 I-03 PI: Azizul Haque, PhD Grant Title: Neuron-specific Enolase and SCI 10-month Technical Progress Report Enolase is a multifunctional glycolytic enzyme involved in growth control, hypoxia,
More informationSupplementary Fig. 1
PDK1-dependent quenching of TACE shedding activity in prion and Alzheimer s diseases Mathéa Pietri, Caroline Dakowski, Samia Hannaoui, Aurélie Alleaume-Butaux, Julia Hernandez-Rapp, Audrey Ragagnin, Sophie
More informationCharlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA
Contribution of Calcium Channel α 2 δ Binding Sites to the Pharmacology of Gabapentin and Pregabalin Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA Disclosure Information Charlie Taylor, PhD
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationModulation of TRP channels by resolvins in mouse and human
July 9, 2015, Ion Channel Retreat, Vancouver Ion Channel and Pain Targets Modulation of TRP channels by resolvins in mouse and human Ru-Rong Ji, PhD Pain Research Division Department of Anesthesiology
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationA new approach to Common Sporadic Alzheimer s, Post-Traumatic Alzheimer s, and CTE:
A new approach to Common Sporadic Alzheimer s, Post-Traumatic Alzheimer s, and CTE: Roles of Aβ, Tau, ApoE, and Regulatory Signaling in Elucidating Pathogenesis and Experimental Therapeutics Sam Gandy,
More informationAnalysis of the Effect of Aggregated β-amyloid on Cellular Signaling Pathways Critical for Memory in Alzheimer s Disease
A p p l i c a t i o n N o t e Analysis of the Effect of Aggregated β-amyloid on Cellular Signaling Pathways Critical for Memory in Alzheimer s Disease Brad Larson, BioTek Instruments, Inc., Winooski, VT,
More informationTherapeutic targeting neuraminidase-1 in multi-stage of tumorigenesis
Therapeutic targeting neuraminidase-1 in multi-stage of tumorigenesis Myron R. Szewczuk Dept. Biomedical and Molecular Sciences, Queen's University, Kingston, K7L 3N6 Ontario, Canada HIGHLIGHTS. An innovative
More informationStewart et al. CD36 ligands promote sterile inflammation through assembly of a TLR 4 and 6 heterodimer
NFκB (fold induction) Stewart et al. ligands promote sterile inflammation through assembly of a TLR 4 and 6 heterodimer a. mrna (fold induction) 5 4 3 2 1 LDL oxldl Gro1a MIP-2 RANTES mrna (fold induction)
More informationKA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders
KA Toulis, K. Dovas, M. Tsolaki The endocrine facets of Alzheimer s disease and dementia-related disorders Sex hormones Calcium metabolism GH/IGF-I Thyroid axis Metabolic hormones + dementia Sex hormones
More informationHerpes Simplex Virus Type 1 and Alzheimer s disease:
The Neurodegenerates Herpes Simplex Virus Type 1 and Alzheimer s disease: Increasing Evidence for a major role of the virus 1 Introduction and Agenda 2 Agenda What is the HSV1 and why is it linked to AD?
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/6/283/ra57/dc1 Supplementary Materials for JNK3 Couples the Neuronal Stress Response to Inhibition of Secretory Trafficking Guang Yang,* Xun Zhou, Jingyan Zhu,
More informationIn vivo reprogramming reactive glia into ipscs to produce new neurons in the
In vivo reprogramming reactive glia into ipscs to produce new neurons in the cortex following traumatic brain injury Xiang Gao 1, Xiaoting Wang 1, Wenhui Xiong 1, Jinhui Chen 1, * 1 Spinal Cord and Brain
More informationThe Comet Assay Tails of the (Un)expected
The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic
More informationMECHANISMS OF PALMITATE INDUCED AMYLOIDOGENESIS IN ALZHEIMER S DISEASE MEDIATED BY ASTROCYTES. Li Liu
MECHANISMS OF PALMITATE INDUCED AMYLOIDOGENESIS IN ALZHEIMER S DISEASE MEDIATED BY ASTROCYTES By Li Liu A DISSERTATION Submitted to Michigan State University In partial fulfillment of the requirements
More informationPreclinical Experience with rhasm for Niemann-Pick Disease
Preclinical Experience with rhasm for Niemann-Pick Disease Gerry Cox, MD, PhD Vice President, Clinical Development September 16, 2014 Shani Niemann-Pick disease Type B UK www.genzyme.com Acid Sphingomyelinase
More informationAn unconventional role for mirna: let-7 activates Toll-like receptor 7 and causes neurodegeneration
An unconventional role for mirna: let-7 activates Toll-like receptor 7 and causes neurodegeneration Sabrina M. Lehmann, Christina Krüger, Boyoun Park, Katja Derkow, Karen Rosenberger, Jan Baumgart, Thorsten
More informationThe Calpain / Calpastatin System in TBI and Chronic Neurodegeneration
The Calpain / Calpastatin System in TBI and Chronic Neurodegeneration Kathryn E. Saatman, Ph.D. Departments of Physiology and Neurosurgery Spinal Cord and Brain Injury Research Center Saatman lab: Dr.
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationAn In Vitro Alternative For Predicting Systemic Toxicity. By: James McKim, Ph.D., DABT Chief Science Officer
An In Vitro Alternative For Predicting Systemic Toxicity By: James McKim, Ph.D., DABT Chief Science Officer What is Systemic Toxicity and What do We Want From Alternative Methods? Toxicity that occurs
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationUsing capillary electrophoresis to detect amyloid protein aggregation
University of Arkansas, Fayetteville ScholarWorks@UARK Chemical Engineering Undergraduate Honors Theses Chemical Engineering 5-2012 Using capillary electrophoresis to detect amyloid protein aggregation
More information2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease
inherited forms of PD The Pathogenesis of Parkinson s Disease February, 2013 PARK1 dominant α-synuclein presynaptic protein PARK2 recessive parkin E3 ubiquitin ligase PARK3 dominant 2p13? PARK4 dominant
More informationSUPPLEMENTARY FIG. S2. Representative counting fields used in quantification of the in vitro neural differentiation of pattern of dnscs.
Supplementary Data SUPPLEMENTARY FIG. S1. Representative counting fields used in quantification of the in vitro neural differentiation of pattern of anpcs. A panel of lineage-specific markers were used
More informationINNOVATION FOR UNMET MEDICAL NEEDS
INNOVATION FOR UNMET MEDICAL NEEDS About Qurient Co. Ltd. Founded in 2008 Headquarter in Seongnam, Gyeonggi-do, Korea Listed on KOSDAQ market with ticker: 115180 Network R&D company: Virtual R&D with a
More information